⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 16, 2024

Figure S3 from Fibronectin contributes to a BRAF inhibitor-driven invasive phenotype in thyroid cancer through EGR1, which can be blocked by inhibition of ERK1/2.

Hannah M. Hicks Nikita Pozdeyev Sharon B. Sams Umarani Pugazhenthi Elise S. Bales Marie‐Claude Hofmann Logan R. McKenna Rebecca E. Schweppe

View at Publisher

Ask AI

Bookmark

Share

Abstract

Figure S3. Sensitivity to BRAF inhibition does not correlate with fibronectin, α5β1 integrin, c-MET, or FAK/Src levels. BRAF inhibition increases fibronectin expression and secretion, which is blocked by ERK1/2 inhibition.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Hicks et al. (2024) studied this question.

synapsesocial.com/papers/68e586c1b6db64358752389c https://doi.org/10.1158/1541-7786.27034876

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Figure S2 from Fibronectin contributes to a BRAF inhibitor-driven invasive phenotype in thyroid cancer through EGR1, which can be blocked by inhibition of ERK1/2.2024
2Figure S4 from Fibronectin contributes to a BRAF inhibitor-driven invasive phenotype in thyroid cancer through EGR1, which can be blocked by inhibition of ERK1/2.2024
3Figure S1 from Fibronectin contributes to a BRAF inhibitor-driven invasive phenotype in thyroid cancer through EGR1, which can be blocked by inhibition of ERK1/2.2024
4Figure S8 from Fibronectin contributes to a BRAF inhibitor-driven invasive phenotype in thyroid cancer through EGR1, which can be blocked by inhibition of ERK1/2.2024
5Figure S6 from Fibronectin contributes to a BRAF inhibitor-driven invasive phenotype in thyroid cancer through EGR1, which can be blocked by inhibition of ERK1/2.2024

More related papers

Figure S5 from Fibronectin contributes to a BRAF inhibitor-driven invasive phenotype in thyroid cancer through EGR1, which can be blocked by inhibition of ERK1/2.2024
Figure S7 from Fibronectin contributes to a BRAF inhibitor-driven invasive phenotype in thyroid cancer through EGR1, which can be blocked by inhibition of ERK1/2.2024
Table S1 from Fibronectin contributes to a BRAF inhibitor-driven invasive phenotype in thyroid cancer through EGR1, which can be blocked by inhibition of ERK1/2.2024